Technology Platform
Cell culture media are critical raw materials for cell preparation, and their quality directly affects the stemness of cells — including their undifferentiated state, self-renewal capacity, and multi-lineage differentiation potential.
Currently, the market offers three major types of culture media:
FBS-Based Medium (Fetal Bovine Serum)
Human Serum-Based Medium
Serum-Free Medium (SFM)
Our products belong to the category of Serum-Free Media, developed through advanced formulation design and component control technologies. Incorporating optimized ratios of nutrients, recombinant proteins, stabilizers, and growth regulators, they provide the following advantages:
▲ Improved cell culture efficiency
▲ Enhanced product stability and batch-to-batch consistency
▲ Full compliance with GMP and clinical application standards, ensuring maximum safety
This technical approach has become the mainstream trend for the large-scale production of cell therapy products, particularly suitable for clinically applied cell types.
Expert Team
Dr. Zikuan Guo
Chief Scientist
Renowned in the industry as the “First Person in Mesenchymal Stem Cell Research in China,” Dr. Guo was among the earliest pioneers to initiate bone marrow mesenchymal stem cell (MSC) studies in the country. He has accumulated extensive experience in large-scale in vitro MSC expansion, functional analysis, and clinical applications. For example, he co-developed innovative projects such as MSC therapy for femoral head necrosis modified with stem cell growth factors, technologies that remain at the forefront in China.
Academic Background:
Ph.D. in Internal Medicine, Beijing Medical University (now Peking University Health Science Center)
Postdoctoral Researcher, Institute of Basic Medicine, Academy of Military Medical Sciences of China
Scientific Achievements:
Dr. Guo was the first in China to carry out bone marrow MSC research. He has led three national “863 Program” projects and three National Natural Science Foundation of China projects, while also participating in multiple other national-level initiatives. As first or corresponding author, he has published over 30 international papers and holds more than 20 national invention patents.
Editorial Roles:
Dr. Guo currently serves as:
Executive Deputy Editor-in-Chief, Chinese Journal of Experimental Hematology
Executive Chief Editor, Chinese Journal of Tissue Engineering Research
Editorial Board Member, Chinese Journal of Cell and Stem Cell, Journal of Tissue Engineering and Reconstructive Surgery, and the World Journal of Stem Cells
Prof. Shouping Ji
Member, Expert Team
Doctoral Supervisor, Institute of Military Medicine, Academy of Military Sciences of China
Council Member, Fujian Society of Cell Biology and Translational Medicine
Committee Member, Xenotransplantation Group, Chinese Medical Association Organ Transplantation Branch
Minjiang Lecture Professor & Tongjiang Distinguished Professor, Fujian Province
Supervisor, Fujian Zoological Society